

54; *Total Annual Responses*: 648; *Total Annual Hours*: 15,390. (For policy questions regarding this collection contact Brian Johnston at 410–786–0143.)

2. Type of Information Collection
Request: Reinstatement with change of a previously approved collection; *Title of Information Collection*: Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery; *Use*: This collection of information is necessary to enable the Agency to garner customer and stakeholder feedback in an efficient, timely manner, in accordance with our commitment to improving service delivery. The information collected from our customers and stakeholders will help ensure that users have an effective, efficient, and satisfying experience with the Agency’s programs. This feedback will provide insights into customer or stakeholder perceptions, experiences and expectations, provide an early warning of issues with service, or focus attention on areas where communication, training or changes in operations might improve delivery of products or services. These collections will allow for ongoing, collaborative and actionable communications between the Agency and its customers and stakeholders. It will also allow feedback to contribute directly to the improvement of program management. Collecting voluntary customer feedback is the least burdensome, most effective way for the Agency to determine whether or not its public websites are useful to and used by its customers. Generic clearance is needed to ensure that the Agency can continuously improve its websites through regular surveys developed from these pre-defined questions. Surveying the Agency websites on a regular, ongoing basis will help ensure that users have an effective, efficient, and satisfying experience on any of the websites, maximizing the impact of the information and resulting in optimum benefit for the public. The surveys will ensure that this communication channel meets customer and partner priorities, builds the Agency’s brands, and contributes to the Agency’s health and human services impact goals. *Form Number*: CMS–10415 (OMB control number 0938–1185); *Frequency*: Occasionally; *Affected Public*: Individuals and Households; *Number of Respondents*: 2,000,000; *Number of Responses*: 2,000,000; *Total Annual Hours*: 60,000. (For policy questions regarding this collection contact

Mohanraj Balasubramanian at 410–786–7808.)

William N. Parham, III,

Director, Division of Information Collections and Regulatory Impacts, Office of Strategic Operations and Regulatory Affairs.

[FR Doc. 2026–20546 Filed 10–6–26; 8:45 am]

BILLING CODE 4169–69–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2022–P–0558]

Determination That Oxandrin (Oxandrolone) Tablets, 2.5 Milligrams and 10 Milligrams, Were Withdrawn From Sale for Reasons of Safety or Effectiveness; Correction

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** of September 13, 2023 (88 FR 62799). The notice announced the determination that Oxandrin (oxandrolone) tablets, 2.5 milligrams (mg) and 10 mg, were withdrawn from sale for reasons of safety or effectiveness. The notice did not include the determination that the abbreviated new drug applications (ANDAs) referencing Oxandrin (oxandrolone) tablets, 2.5 mg and 10 mg, were also determined to be withdrawn from sale for reasons of safety or effectiveness and that these ANDAs would be removed from “Approved Drug Products With Therapeutic Equivalence Evaluations,” which is known generally as the “Orange Book.” This notice corrects that error.

FOR FURTHER INFORMATION CONTACT: Kimberly Lehrfeld, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6250, Silver Spring, MD 20993–0002, 301–796–3137, Kimberly.Lehrfeld@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of September 13, 2023, appearing on pages 62799 and 62800 in FR Doc. 2023–19796, the following corrections are made:

1. On page 62799, in the first column, before the last sentence in the **SUMMARY** section, the following sentence is added: Additionally, FDA has determined that Par Pharmaceutical Inc.’s ANDA 077827 for oxandrolone tablets, 2.5 mg and 10 mg; Roxane Laboratories, Inc.’s

ANDA 077249 for oxandrolone tablets, 2.5 mg and 10 mg; Sandoz Inc.’s ANDA 076897 for oxandrolone tablets, 2.5 mg and 10 mg; and Upsher Smith Laboratories LLC’s ANDA 076761 for oxandrolone tablet, 2.5 mg, and ANDA 078033 for oxandrolone tablet, 10 mg, that all reference Oxandrin (oxandrolone) tablets, 2.5 mg and 10 mg, were also withdrawn for reasons of safety or effectiveness.

2. On page 62799 in the third column, the second paragraph is corrected to read as follows:

In a letter dated March 26, 2019, Gemini requested that FDA withdraw approval of NDA 013718 for Oxandrin (oxandrolone) tablets, 2.5 mg and 10 mg, under § 314.150(c) (21 CFR 314.150(c)), stating that the product was no longer being marketed. Subsequently, on December 16, 2022, FDA notified Gemini and other holders of approved applications for oxandrolone tablets, 2.5 mg and 10 mg, that the Agency believes a potential problem associated with oxandrolone tablets is sufficiently serious that the drug products should be removed from the market, and to enable withdrawal of approval of their applications under § 314.150(d). After FDA notified Gemini that it believes the potential problems associated with the drugs are sufficiently serious that the drugs should be removed from the market pursuant to § 314.150(d), Gemini requested in a letter dated December 19, 2022, that FDA withdraw approval of NDA 013718 for Oxandrin (oxandrolone) tablets, 2.5 mg and 10 mg, under § 314.150(d). Similarly, after notification by FDA, the following holders of approved ANDAs requested withdrawal of their applications under § 314.150(d) and waived their opportunity for a hearing: Par Pharmaceutical Inc. for ANDA 077827 for oxandrolone tablets, 2.5 mg and 10 mg; Sandoz Inc. for ANDA 076897 for oxandrolone tablets, 2.5 mg and 10 mg; and Upsher Smith Laboratories LLC for ANDA 076761 for oxandrolone tablet, 2.5 mg, and ANDA 078033 for oxandrolone tablet, 10 mg. In the **Federal Register** of June 28, 2023 (88 FR 41970), FDA announced that it was withdrawing approval of NDA 013718, ANDA 077827, ANDA 076897, ANDA 076761, and ANDA 078033, effective June 28, 2023. Additionally, Roxane Laboratories, Inc. previously requested withdrawal of its ANDA 077249 for oxandrolone tablets, 2.5 mg and 10 mg, and waived its opportunity for a hearing. In the **Federal Register** of May 19, 2009 (74 FR 23407), FDA announced that it was withdrawing approval of ANDA 077249, effective June 18, 2009.

3. On page 62800 at the top of the second column, at the end of the first paragraph, the following two sentences are added:

Likewise, FDA has determined under § 314.161 that those ANDAs that used Oxandrin (oxandrolone) tablets, 2.5 mg and 10 mg, approved in NDA 013718 as their reference listed drug were withdrawn for reasons of safety or effectiveness. Accordingly, the Agency will remove Par Pharmaceutical Inc.'s ANDA 077827 for oxandrolone tablets, 2.5 mg and 10 mg; Roxane Laboratories, Inc.'s ANDA 077249 for oxandrolone tablets, 2.5 mg and 10 mg; Sandoz Inc.'s ANDA 076897 for oxandrolone tablets, 2.5 mg and 10 mg; and Upsher Smith Laboratories LLC's ANDA 076761 for oxandrolone tablet, 2.5 mg, and ANDA 078033 for oxandrolone tablet, 10 mg, from the list of drug products published in the Orange Book per § 314.162.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026–20503 Filed 10–6–26; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Clinical Center; Notice of Closed Meeting

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the Board of Scientific Counselors of the NIH Clinical Center.

The meeting will be closed to the public as indicated below in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual grant applications conducted by the Clinical Center, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Board of Scientific Counselors of the NIH Clinical Center.

Date: October 26–27, 2026.

Time: 9:30 a.m. to 1:00 p.m.

Agenda: The Review and Discussion of the Department of Perioperative Medicine, Department of Transfusion Medicine, and Rehabilitation Medicine Department.

Address: National Institutes of Health Clinical Center, Building 10, 10 Center Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Leighton Chan, Ph.D., Chief Scientific Officer/Scientific Director, National Institutes of Health, 10 Center Drive, Bethesda, MD 20892, (301) 496–4733, chanle@cc.nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Dated: October 5, 2026.

Rosalind M. Niamke,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2026–20557 Filed 10–6–26; 8:45 am]

BILLING CODE 4167–05–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Digestive, Kidney and Urological Systems Integrated Review Group; Pathobiology of Kidney Disease Study Section.

Date: November 4–5, 2026.

Time: 9:00 a.m. to 6:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Jason D. Hoffert, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301–496–9010, hoffertj@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Pulmonary and Vascular Pathobiology, Hemostasis and Thrombosis.

Date: November 4, 2026.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Vladimir Bogdanov, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Dr., Room 801G, Bethesda, MD 20892, 301–594–6602, bogdanovv2@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Social, Biobehavioral, and Population Health: NIH Collaborative International Research Projects (PF5)—Panel A.

Date: November 4–5, 2026.

Time: 9:00 a.m. to 5:30 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Shareen Iqbal, Ph.D., MPH, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301–594–0683, iqbalsha@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Fellowships: Basic Neurosciences.

Date: November 4–5, 2026.

Time: 9:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Baila Sara Hall, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301–435–1722, baila.hall@nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Training and Career Development: Clinical Care, Treatment & Disease Management.

Date: November 4–5, 2026.

Time: 9:00 a.m. to 9:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Trina Colleen Salm Ward, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301–594–5254, salmwardtc@csr.nih.gov.

Name of Committee: Center for Scientific Review Special Emphasis Panel; Training: Biomedical Sciences.

Date: November 4–5, 2026.

Time: 9:30 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Address: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892.

Meeting Format: Virtual Meeting.

Contact Person: Sonia Ivette Ortiz-Miranda, Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, 301–496–3859, sonia.ortiz-miranda@nih.gov.